1. COVID-19 Therapeutics Use by Social Deprivation Index in England, July 2020–April 2023.
- Author
-
Falola, Angela, Squire, Hanna, Bou-Antoun, Sabine, Løchen, Alessandra, Brown, Colin S., and Demirjian, Alicia
- Subjects
COVID-19 treatment ,ANTIVIRAL agents ,HEALTH equity ,MONOCLONAL antibodies - Abstract
Coronavirus disease-19 (COVID-19) has disproportionately affected certain demographics in England, exacerbating existing health disparities. Effective therapeutics are a critical line of defence against COVID-19, particularly for patients at elevated risk for severe disease. Surveillance systems were established to monitor the usage of COVID-19 therapeutics in hospital and community settings and to inform stewardship. Three antiviral therapies—nirmatrelvir plus ritonavir (Paxlovid
® ), remdesivir (Veklury® ), and molnupiravir (Lagevrio® )—and two neutralising monoclonal antibody therapies (nMAbs)—sotrovimab (Xevudy® ) and casirivimab with imdevimab (Ronapreve® )—were in use in England between July 2020 and April 2023. This paper aims to illuminate trends in the utilisation of COVID-19 therapeutics treatment in both hospital and community settings, stratified by the Index of Multiple Deprivation (IMD) in England. Chapter 3 of the English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) Report 2022 to 2023 also discusses the epidemiological surveillance of these five directly acting antiviral COVID-19 therapeutics' use in England between 2022 and 2023. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF